FDA Approves Inflectra, a Biosimilar to Remicade, to Treat Ulcerative Colitis and Crohn’s

FDA Approves Inflectra, a Biosimilar to Remicade, to Treat Ulcerative Colitis and Crohn’s
Celltrion announced that the U.S. Food and Drug Administration (FDA) approved Inflectra (biosimilar infliximab) for all indications of the reference product Remicade (infliximab), marketed in the country by Janssen Biotech, Inc. Inflectra is an anti-inflammatory medicine that contains the active substance infliximab, and indicated for reducing symptoms of adult ulcerative colitis, and adult and pediatric Crohn’s disease, as well as psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, and plaque psoriasis. “The FDA approval of INFLECTRA, just the second biosimilar to be approved in the U.S., is significant for the medical c
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *